Dawaa Reference

infectious

COVID-19 (mild, outpatient)

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources4 sources

Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044) · NICE Guideline NG191: Managing COVID-19 2023 · NIH COVID-19 Treatment Guidelines 2023 · WHO Therapeutics and COVID-19: Living Guideline 2023

Verified against5 documents
  • Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044)
  • NIH COVID-19 Treatment Guidelines 2023
  • WHO Therapeutics and COVID-19: Living Guideline 2023
  • COVID-19 (mild, outpatient) - disease-level clinical article (covid-19-outpatient-clinical.txt)
  • MSF Essential Drugs 2024 - paracetamol (oral) for the antipyretic figures: "Adult: 1 g 3 or 4 times daily (max. 4 g daily)" and "Child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily)". The hydration, rest and saturation monitoring are supportive measures from the WHO Therapeutics and COVID-19: Living Guideline 2023, which is not held in this corpus.

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (4)

  • Most symptomatic patients report fever, cough, and shortness of breath [breathlessness · cough · fever]
  • Sore throat, loss of smell or taste, malaise, myalgia, and diarrhea are less common symptoms [diarrhoea · loss of smell · malaise · muscle pain · sore throat]
  • About 17.9% to 33.3% of those infected have no symptoms at all
  • Mild illness has typical COVID symptoms but no breathlessness and normal chest imaging

Signs — what you find (3)

  • Moderate illness features lower respiratory disease with oxygen saturation of 94% or higher on room air
  • Severe illness shows SpO2 below 94%, a respiratory rate over 30 per minute, or lung infiltrates over 50% of lung volume
  • Pseudo-chilblain-like acral lesions are the most common skin finding, seen in about 40% of cases

Tests (6)

  • Nasopharyngeal PCR for SARS-CoV-2 RNA is the standard diagnostic test
  • Antigen tests are faster but less sensitive than PCR
  • Serologic (antibody) testing is not recommended to diagnose acute infection
  • D-dimer level helps choose between therapeutic and prophylactic anticoagulation dosing
  • Chest x-ray is normal in about one in five patients despite confirmed infection
  • Routine chest CT is not advised for screening or diagnosing COVID-19

If not this — what else fits (5)

  • Community-acquired bacterial pneumonia is on the differential list
  • Influenza infection is a key differential given the overlapping symptoms
  • Aspiration pneumonia is on the differential list
  • Pneumocystis jirovecii pneumonia is a differential, notably in immunocompromised patients
  • Pulmonary tuberculosis is on the differential list

SourceStatPearls "Features, Evaluation, and Treatment of Coronavirus (COVID-19)" - disease-level clinical article

Presentation findings are traced to the source above.

1

SUPPORTIVE CARE AND SYMPTOM MANAGEMENT

1st line
Adult dose and duration

Symptomatic relief with an antipyretic (paracetamol 1 g 3 or 4 times daily, max. 4 g daily), adequate hydration, rest, and monitoring oxygen saturation (SpO2) x 5-10 days

Paediatric dose
Dose by age
Paracetamol, child 1 month and over:15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily). Child under 1 month: 10 mg/kg 3 or 4 times daily (max. 40 mg/kg daily). Ensure adequate hydration and monitor for red flag signs (respiratory distress, lethargy).
Dose source

MSF Essential Drugs 2024 - paracetamol (oral) for the antipyretic figures: "Adult: 1 g 3 or 4 times daily (max. 4 g daily)" and "Child 1 month and over: 15 mg/kg 3 or 4 times daily (max. 60 mg/kg daily)". The hydration, rest and saturation monitoring are supportive measures from the WHO Therapeutics and COVID-19: Living Guideline 2023, which is not held in this corpus.

Why

For mild COVID-19 in low-risk outpatient individuals without risk factors for severe disease, specific antiviral therapy is not indicated; supportive care is standard

Cautions
  • Refer urgently to hospital if SpO2 falls below 94% on room air, or if patient develops severe dyspnoea, confusion, or persistent chest tightness.
  • Routine antibiotics, systemic corticosteroids, or hydroxychloroquine are NOT recommended for mild outpatient COVID-19 without bacterial coinfection.
2

REFERRAL & SAFETY-NETTING (NO DRUG THERAPY)

1st line
Dose source

COVID-19 (mild, outpatient) - disease-level clinical article (covid-19-outpatient-clinical.txt)

Why

Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.

Cautions
  • RED FLAG - Monitor for sudden clinical deterioration leading to acute respiratory failure or ARDS.
3

NIRMATRELVIR / RITONAVIR

2nd line

Strength300 mg

Formoral.solid

Adult dose and duration

Nirmatrelvir 300 mg (two 150 mg tablets) plus Ritonavir 100 mg (one 100 mg tablet) taken together twice daily (start within 5 days of symptom onset) x 5 days

Paediatric dose

(Approved for adolescents >=12 years weighing at least 40 kg at adult dose (300 mg / 100 mg BID for 5 days). Not recommended in children <12 years.)

Dose by age
12 years and over:300 mg / 100 mg twice daily for 5 days (as for adults), for adolescents weighing at least 40 kg.
Dose source

NIH COVID-19 Treatment Guidelines 2023

Why

For high-risk outpatients within 5 days of symptoms. Paxlovid has little retail presence in Egypt - see molnupiravir below for what is actually on the shelf.

Cautions
  • Severe drug interaction potential due to CYP3A inhibition by ritonavir; perform comprehensive medication reconciliation before prescribing.
  • Contraindicated in severe renal impairment (eGFR <30 mL/min) and severe hepatic impairment (Child-Pugh Class C).
  • Requires dose adjustment in moderate renal impairment (eGFR 30-59 mL/min: Nirmatrelvir 150 mg + Ritonavir 100 mg BID).
Egyptian brands

No Egyptian brand matched — prescribe by generic name.

4

MOLNUPIRAVIR

2nd line

Strength200 mg

Formoral.solid

Adult dose and duration

800 mg - four 200 mg capsules - every 12 hours for 5 days, started within 5 days of symptom onset x 5 days exactly

Paediatric dose

Not for use under 18 years - no safety or efficacy data.

Choice

Availability decides. Nirmatrelvir/ritonavir has no Egyptian product in the register; molnupiravir has 8.

Dose source

Lagevrio 200 mg hard capsules SmPC sections 4.2 and 4.4 (eMC product 13044)

Why

The antiviral that is actually registered and stocked in Egypt: eight products, 318-624 EGP for the whole 40-capsule course. Read the cautions before reaching for it - the evidence is weaker than the price suggests.

Cautions
  • PANORAMIC, the large trial in vaccinated high-risk adults in the community, found no reduction in hospital admission or death. WHO's recommendation is conditional and confined to those at highest risk. In a vaccinated patient this is 300-600 EGP for a benefit that has not been shown.
  • Not recommended in pregnancy - animal reproductive toxicity. A woman who could become pregnant needs effective contraception during the course and for 4 days after the last dose.
  • Exactly 5 days. Longer has not been studied and there is no reason to extend it.
  • No dose change needed for renal or hepatic impairment.
Egyptian brands
Egyptian brandManufacturerIndicative price
MOLNUVOC 200 MG 40 CAPS.AMOUN318.00 EGP (7.95/unit)
MOLNUPRAVA 200 MG 40 CAPS.EUROPEAN EGYPTIAN PHARM. IND.420.00 EGP (10.50/unit)
PIROLOGLOB 200 MG 40 CAPS.GLOBAL ADVANCED PHARMACEUTICALS (GAP)420.00 EGP (10.50/unit)
COVAPRAVIR 200 MG 40 CAPS.EIPICO461.00 EGP (11.53/unit)
MOLNUPIRAVIR-EVA 200 MG 40 CAPS.EVA PHARMA461.00 EGP (11.53/unit)
MOLNUPIRAVIR-RAMEDA 200 MG 40 CAPS.RAMEDA461.00 EGP (11.53/unit)
AUGIPRIVIR 200 MG 40 CAPS.AUG PHARMA624.00 EGP (15.60/unit)
HOCHSTERPRIVER 200 MG 40 CAPS.HOCHSTER PHARMACEUTICAL INDUSTRIES624.00 EGP (15.60/unit)

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.